EMEA-001426-PIP01-13-M02

Key facts

Active substance
Recombinant varicella zoster virus (VZV) glycoprotein E
Therapeutic area
Vaccines
Decision number
P/0222/2018
PIP number
EMEA-001426-PIP01-13-M02
Pharmaceutical form(s)
Powder and suspension for suspension for injection
Condition(s) / indication(s)
Prevention of varicella zoster virus (VZV) reactivation
Route(s) of administration
Intramuscular use
Contact for public enquiries
GlaxoSmithKline Biologicals SA

Tel. +44 (0)20 8966 3220
E-mail: eu.paediatric-plans@gsk.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating